Edition:
United Kingdom

People: Akebia Therapeutics Inc (AKBA.OQ)

AKBA.OQ on NASDAQ Stock Exchange Global Market

3.88USD
19 Jul 2019
Change (% chg)

$0.04 (+1.04%)
Prev Close
$3.84
Open
$3.88
Day's High
$3.96
Day's Low
$3.77
Volume
268,931
Avg. Vol
403,846
52-wk High
$10.73
52-wk Low
$3.72

Jain, Rita 

Ms. Rita I. Jain, M.D. is Senior Vice President, Chief Medical Officer of the Company. Dr. Jain joined Akebia as Senior Vice President, Chief Medical Officer in May 2017. Prior to joining Akebia, Dr. Jain was the Vice President of Men’s and Women’s Health and Metabolic Development at AbbVie Inc. (NYSE: ABBV), a research-based global pharmaceutical company. From 2003 to 2016, she held positions of increasing responsibility, with over 10 years as either a Divisional Vice President or Vice President in Pharmaceutical Development at Abbott Laboratories, and after the AbbVie’s split from Abbott in 2013, at AbbVie. In addition to her work in Men’s and Women’s Health and Metabolic Development, she also led activities in Pain, Respiratory and Cystic Fibrosis Development. Before AbbVie, she held management positions in the Arthritis, Inflammation and Pain Group at Searle (acquired by Pharmacia and subsequently Pfizer). Prior to joining Searle, Dr. Jain was a faculty member at North Shore University Hospital in New York, with an academic appointment as Assistant Professor of Medicine, NYU School of Medicine. Dr. Jain has served on the Board of Directors of ChemoCentryx, Inc., (Nasdaq: CCXI) since March 2019. Dr. Jain received her B.S. in Biology from LIU/CW Post and her M.D. from the State University of New York at Stony Brook School of Medicine. Dr. Jain completed her training in Internal Medicine at Staten Island University Hospital followed by a Fellowship in Rheumatology at North Shore University Hospital and a Clinical Research Fellowship at the University of Texas Southwestern Medical Center, Dallas.

Basic Compensation

Total Annual Compensation, USD 429,884
Restricted Stock Award, USD 420,420
Long-Term Incentive Plans, USD --
All Other, USD 585,514
Fiscal Year Total, USD 1,435,820

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Adrian Adams

133,436

John Butler

3,471,070

Jason Amello

1,091,020

Nicole Hadas

--

Steven Burke

--

Michel Dahan

1,276,790
As Of  31 Dec 2018